4DMT gene therapy cuts need for Eylea in wet AMD trial

A mid-stage trial of 4D Molecular Therapeutics gene therapy for eye disease age-related macular degeneration (AMD) 4D-150 has shown promising signs of efficacy, plus a reduced need for injections into the eye with current therapy Eylea.